FAQ/Help |
Calendar |
Search |
Today's Posts |
|
Parkinson's Disease Clinical Trials For posting and discussion of clinical trials related to Parkinson's Disease, and for the Parkinson Pipeline Project. All are welcome. |
Reply |
|
Thread Tools | Display Modes |
05-31-2007, 06:43 PM | #1 | |||
|
||||
Magnate
|
Safety Study of Gene Transfer Therapy in People with Parkinson’s Disease
Official Study Title: A Phase 1 Open-label Safety Study of Intrastriatal Infusion of Adeno-Associated Virus Encoding Human Aromatic L-Amino Acid Decarboxylase (AAV-hAADC-2) in Subjects with Mid- to Late- Stage Parkinson’s Disease Sponsor: Genzyme Clinicaltrials.gov ID : NCT00229736 Study ID : AAV-hAADC-2-003 Last Updated Date: 02 Mar 2007 Trial Start Date: 01 Nov 2004 Trial Post date: 02 Mar 2007 Website URL: http://www.pdtrials.org/front/trial_...p?trial_id=139 Summary In people with Parkinson’s disease (PD), the part of the brain called the substantia nigra progressively loses the ability to send dopamine signals to the striatum, another part of the brain. As a result, dopamine levels are lacking in people diagnosed with PD. The purpose of this study is to determine the safety of an investigational drug, AAV-hAADC-2. This gene therapy drug works to provide an essential enzyme in the brain that will enable L-dopa – a drug commonly used to treat PD- to convert to dopamine in the brain. Participants for this study will receive a surgical injection of this drug into the brain, then undergo periodic clinical evaluations and brain scans. They will also continue to take L-dopa while taking part on this study. The primary objective of the study is to determine the safety of intrastriatal administration of AAV-hAADC-2. A secondary objective is to determine the effect of AAV-hAADC-2 on clinical status. Enrollment Expected Enrollment: 15 Trial Phase Study Phase: Phase 1 Symptoms #Trial does not specify symptoms Time Commitment Length of Time Commitment: More than six months Frequency of office visits: Every 2 weeks for the first 3 months, once a month for the next 9 months, then once every 3 months for the next 4 years. Eligibility Minimum Age: 40 Maximum Age: 75 Inclusion Criteria
Primary Contact Rowena Mah Study Coordinator University of California, San Francisco (UCSF) Phone : 415-476-0947 rowenam@itsa.ucsf.edu San Francisco, CA 94143 USA redline.jpg Full Details: PDTrials.org http://www.pdtrials.org/front/trial_...p?trial_id=161ClinicalTrials.gov http://clinicaltrials.gov/ct/show/NCT00427674?order=1[LIST][*]Complete list of PD trials redline.jpg Parkinson Pipeline Project www.pdpipeline.org Following theapies from pre-clinical development to approval in the Parkinson Pipeline Project Database (see homepage for link to database) redline.jpg
__________________
You're alive. Do something. The directive in life, the moral imperative was so uncomplicated. It could be expressed in single words, not complete sentences. It sounded like this: Look. Listen. Choose. Act. ~~Barbara Hall I long to accomplish a great and noble tasks, but it is my chief duty to accomplish humble tasks as though they were great and noble. The world is moved along, not only by the mighty shoves of its heroes, but also by the aggregate of the tiny pushes of each honest worker. ~~Helen Keller |
|||
Reply With Quote |
Reply |
|
|
Similar Threads | ||||
Thread | Forum | |||
CLINICAL TRIAL...PD Associated Risk Study (PARS): Eval. Potential Screening Tools | Parkinson's Disease Clinical Trials | |||
Ceregene Gene Therapy Trial Phase II | Parkinson's Disease Clinical Trials | |||
TRIAL: Safety Study of 123-I MZINT | Parkinson's Disease Clinical Trials | |||
Parkinson's Disease Gene Transfer Called Safe | Parkinson's Disease | |||
Successful one year gene therapy trial announced by Neurologix | Parkinson's Disease |